AKCA
$18.14
Akcea Therapeutics
$.01
.06%
AKCA
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.34)
Revenue:  $46.20 Mil
Tuesday
Nov 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AKCA reports earnings?
Beat
Meet
Miss

Where is AKCA's stock price going from here?
Up
Flat
Down
Stock chart of AKCA
Analysts
Summary of analysts' recommendations for AKCA
Score
Grade
Pivots
Resistance
$18.17
$18.16
$18.15

$18.14

Support
$18.13
$18.12
$18.11
Tweet
Growth
Description
Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.